Integrin/cytokine receptor interaction provides permissive signals leading to neoangiogenesis, and integrins are crucial for differentiation of endothelial progenitor cells (EPCs). It is known that the inflammatory interleukin-3 (IL-3), released in the tumoral microenvironment, contributes to both angiogenesis and vasculogenic processes. Herein, we generated IL-3 receptor beta common (IL-3Rbc) extracellular domain-derived fusion proteins (Fc) to elucidate the molecular mechanisms regulating these processes. Three different Fc were generated, containing the entire extracellular domain of IL-3Rbc (Fc1.4), a fragment corresponding to domains 1-3 (Fc1.3) and a fragment corresponding to domain 4 (Fc4), respectively. The ability of the fusion proteins to interfere with IL-3Rbc/b1 integrin interaction was assessed on endothelial cells (ECs), EPCs and murine-derived ECs. Pull-down experiments showed that Fc1.4 and Fc4 fusion proteins specifically interacted with b1 integrin. Fc4 and Fc1.4 fragments prevented IL-3-mediated EPC expansion, arterial morphogenesis and tumour-derived EC migration, without affecting cell adhesion. Fc4 in vivo inhibited the IL-3-mediated vasculogenic process, as well as inflammatory and tumour vascular growth. In conclusion, these data identify the b1 integrininteracting domain in the juxta-membrane IL-3Rbc extracellular domain, and provide the rational for targeting this interaction to impair vascular growth.
Introduction
Neovascularization is orchestrated by a complex set of growth factors (Folkman, 2006) . It has been reported that the T-cell-derived pro-inflammatory cytokine interleukin-3 (IL-3), released in breast and ovarian cancer microenvironment, contributes to this process (Dentelli et al., 2004) . IL-3 effects are mediated by the IL-3 receptor (IL-3R), belonging to the cytokine receptor superfamily. It consists of an a-subunit, essential to the activation of the b common subunit (IL-3Rbc), believed to be the main signalling entity (Bazan, 1990; Tavernier et al., 1991) . As shown by structure analysis (Carr et al., 2001) , the extracellular domain of the IL-3Rbc consists of four domains: domain 1 is required for the activation of IL-3Rbc; domain 3 is characterized by four cysteine residues forming two disulphide bridges; and domains 2 and 4 are classical fibronectin-type III domains. Domain 4 houses the W-S-X-W-S motif, which is similar to those of other class I cytokine receptors. The IL-3Rbc extracellular domain is followed by 20 amino-acid residues (corresponding to the membrane spanning segment) and by a cytoplasmic domain lacking detectable catalytic activity. In addition, phosphorylation of tyrosine residues in this region is involved in IL-3-mediated signal transduction (Yoshimura et al., 1995; Reddy et al., 2000) . As a result of IL-3Rbc activation, the signal transduction and activator of transcription 5 (STAT5) undergoes phosphorylation and ultimately regulates the expression of genes involved in different cell functions (Buitenhuis et al., 2004) both in haemopoietic (Mui et al., 1995) and vascular tissues .
Tumour neoangiogenesis is supported by sprouting cells, co-option of neighbouring pre-existing vessels and by mobilization and incorporation of several cell types, including resident and bone marrow-derived endothelial progenitor cells (EPCs) (Ahn and Brown, 2009 ). Compelling evidence indicates that integrin signals, besides controlling the fate of mature endothelial cells, also modulate differentiation of endothelial progenitors into mature cells (Bellik et al., 2005) . In addition, tissuespecific extracellular matrix, adhesion molecules and cytokines expressed at the neoangiogenetic sites are crucial for the selective homing and differentiation of progenitor cells. Among the integrins involved in these processes, the a5b1 has attracted considerable interest (Silva et al., 2008) . Indeed, for triggering IL-3-mediated expansion and arterial specification of both circulating and bone marrow-derived EPCs, matrix ligand occupancy of a5b1 integrins is essential (Zeoli et al., 2008) . Some signalling enzymes are regulated by both integrins and growth factor/cytokine receptors, providing key nodal points at which the two system can interplay (Giancotti and Tarone, 2003) . In addition, since integrins are relatively stable and the extracellular matrix is not diffusible, integrins determine whether a cell is able to respond to the more temporal signals provided by diffusible factors. Integrins are therefore positional checkpoints for cell-fate decisions induced by growth factors and cytokines. For vessel morphogenesis, both in physiological and pathological settings, a coordinated regulation of cell proliferation, migration and differentiation into tubules is required. This provides an elegant example of cooperation between growth factors/cytokines and integrin-extracellular matrix adhesion for an optimal output of sustained synergistic signalling (Streuli and Akhtar, 2009 ).
Tumour neovascularization is crucial for growth and invasion of tumour cells, as vasculature provides metabolic support for tumour cells, and serves as a gatekeeper for their escape and entry into the circulation (Furuya et al., 2009) . Thus, because of their critical role in tumour growth, tumour blood vessels are recognized as potential antitumoral drug targets. However, clinical trials with factors that block different aspects of angiogenesis for treatment of human cancers have not been as effective as expected (Shaked and Kerbel, 2007; Shaked et al., 2008; Shojaei and Ferrara, 2008) .
In this study, we attempted to elucidate how mechanistically IL-3Rbc and b1 integrin cooperate to regulate IL-3-mediated vasculogenesis and tumour angiogenesis to provide a rational basis to develop novel compounds able to interfere with vascular growth in cancer.
Results
For EPC expansion in response to IL-3 a functional IL-3Rbc/b1 molecular complex is required Co-immunoprecipitation experiments supported a potential role of b1 integrin in regulating the fate of EPCs exposed to IL-3, showing that the IL-3Rbc interacts with b1 integrin (Figure 1a) . To investigate the biological relevance of the IL-3Rbc/b1 integrin complex, an IL-3R mutant lacking the intracellular domain (D455) (Defilippi et al., 2005) was transfected into EPCs. As in mature endothelial cells (Defilippi et al., 2005) , the D455 mutant still retained the ability to interact with b1 integrin. Similarly, in EPCs expressing the D455 mutant, IL-3 stimulation failed to induce STAT5 activation and progression into the cell cycle (Figure 1b) , indicating that for IL-3-mediated EPC expansion, a functional IL-3Rbc/b1 integrin complex is required. Consistently, b1 integrin depletion, either by silencing or by using an anti-b1 integrin-blocking antibody (Figure 1c ), prevented EPC cell-cycle progression in response to IL-3.
IL-3Rbc extracellular domain is involved in b1 integrin interaction Integrins, by cooperating with growth factors and cytokine receptors, control vascular tissue development (Giancotti and Tarone, 2003) . To analyse the mechanism of interaction between IL-3Rbc and b1 integrin, we first generated a construct containing the IL-3Rbc intracellular region and the haemagglutinin-tagged myristylated c-Src domain (Myr-bc) (Supplementary Figure  S1) . This construct was then co-transfected with the asubunit of IL-3R into human embryonic kidney 293 (HEK293) cells. HEK293 cells transfected with the asubunit of IL-3R together with the full-length-beta common were used as controls. Expression and cell anchorage of Myr-bc construct (a 66 kDa protein) are shown in Supplementary Figure S2A (left and right panels, respectively). Myr-bc/b1 integrin functional interaction was evaluated by co-immunoprecipitation experiments. Data reported in Supplementary Figure S2B revealed that the Myr-bc construct was unable to interact with b1 integrin. Moreover, consistent with the crucial role of IL-3Rbc/b1 integrin interaction in regulating downstream signalling pathways, IL-3 failed to activate STAT5 in HEK293 cells expressing the Myrbc mutant. By contrast, IL-3 was still able to activate the Figure 2b show that, unlike Fc1.3, Fc1.4 and Fc4 were able to pull down b1 integrin in cell extracts from IL-3-cultured EPCs. The Fc portion of human immunoglobulin G (IgG) was used as a negative control (Figure 2b ). Similar results were obtained in pull-down experiments with endothelial cell extracts (Supplementary Figure S3A) . Thus, these results identify the IL-3Rbc juxta-membrane region as the b1 integrin-interacting domain.
Soluble Fc1.4 and Fc4 fusion proteins prevent IL-3-mediated EPC expansion and arterial specification, as well as EC proliferation and migration Fc1.4, Fc1.3 and Fc4 recombinant proteins were used in functional studies as tools for interfering with IL-3Rbc/ b1 integrin-mediated EPC expansion and differentiation. Soluble Fc1.4, Fc1.3 or Fc4 proteins were added to IL-3-cultured EPCs to analyse STAT5 activation and cyclin D1 expression. Both STAT5 activation and cyclin D1 expression were reduced when Fc1.4 and Fc4 were added to IL-3-cultured EPCs ( Figure 3a) . Consistently, data reported in Figure 3b show that these events correlated with inhibition of EPC cell-cycle progression, without affecting cell adhesion ( Figure 3c ). Besides affecting EPC expansion, IL-3 also induces their arterial differentiation (Zeoli et al., 2008) . Indeed, IL-3-cultured EPCs acquired arterial commitment (EphrinB1, EphrinB2 and Notch4 expression), but failed to undergo venous (negative EphB4 expression) or lymphatic (negative vascular endothelial growth factor receptor-3 (VEGFR3) and lymphatic vessel endothelial hyaluronan receptor-1 expression) specification ( Figure 3d ) (Gro¨ger et al., 2004; Ma¨kinen et al., 2005) . Consequently, the effects of soluble Fc proteins on the expression of specific arterial markers were evaluated. Data reported in Figure 3d show that IL-3 failed to induce the expression of EphrinB2, EphrinB1 and Notch4 arterial markers in EPCs cultured in the presence of Figure S4A ) and Fc1.4 (data not shown) were unable to pull down different concentrations of recombinant human IL-3 indicates that they did not compete with IL-3. Moreover, the specificity of Fc fusion proteins for the IL-3Rbc/b1 integrin complex was confirmed by the observation that VEGF, in the presence of Fc fusion proteins, was still able to induce activation of the receptor tyrosine kinase, STAT5 as well as extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signalling pathways in EPCs (Supplementary Figure S4B) .
Soluble Fc1.4 and Fc4 fusion proteins impair H-END migration
Growth factor receptors and matrix receptor proteins are known to modulate vessel formation in tumours either by inducing endothelial cell proliferation or by affecting cell migration (Guo and Giancotti, 2004) . H-END cells, implanted in syngeneic mice, typically form tumours similar to haemoangiosarcoma and Kaposi's sarcoma (Biancone et al., 1999) . Our previous observation that the number of vessels inside the tumour was reduced when H-END cells were transfected with the D455 mutant led us to investigate the functional relevance of the IL-3Rbc/b1 integrin interplay in regulating tumour angiogenesis. Expression of IL-3Rbc/b1 integrin molecular complex was evaluated and reported in Figure 4a . As H-END cells acquire the ability to migrate via STAT5 activation Figure 2 The juxta-membrane IL-3Rbc extracellular region is the b1 integrin-interacting domain. (a) Fc fusion proteins were generated in PFUSE-hIgG1-Fc1 plasmid vector using three different fragments of the IL-3Rbc extracellular portion: (i) the entire extracellular domain of the IL-3Rbc (Fc1.4); (ii) the fragment corresponding to domains 1-3 (Fc1.3); and (iii) the fragment corresponding to the juxta-membrane domain (Fc4). (b) Pull-down experiment was performed on EPCs using Fc1.3, Fc1.4, Fc4 fragments or the Fc portion of human IgG, as a negative control.
in response to IL-3 , the effects of Fc fusion proteins were first analysed by functional and biochemical studies. Data reported in Figure 4b show that soluble Fc1.4 and Fc4, unlike Fc1.3, were able to prevent both IL-3-mediated STAT5 activation and cell migration (Figure 4c ), whereas cell adhesion was not affected (Figure 4d ).
Fc1.4 and Fc4, but not Fc1.3, prevent IL-3-induced inflammatory and tumour angiogenesis There is an undeniable link between inflammation and tumour angiogenesis (Naldini and Carraro, 2005) . Thus, the effects of Fc fusion proteins on vascular growth were first evaluated in the FVB mouse, which has been shown to provide a suitable inflammatory angiogenic model (Brizzi et al., 1999; Dentelli et al., 1999) . FVB mice were injected subcutaneously (s. IL-3Rbc/b1 integrin complex: a novel antiangiogenetic target B Uberti et al marrow or the novo clonal formation of blood vessels from these cells (Ahn and Brown, 2009; Gao et al., 2009) . To date, there is no conclusive data available on the role of integrins in regulating adult vasculogenic process. To address this issue, a vasculogenic assay was performed as described previously (Zeoli et al., 2008; Togliatto et al., 2010) . Severe combined immune deficiency (SCID) mice were injected s.c. with Matrigel containing EPCs, IL-3 and soluble Fc1.3, Fc1.4, Fc4 or the Fc portion of human IgG, as control. Data reported in Figure 5c clearly show that Fc1.4 or Fc4 injection prevented vessel formation in SCID mice. These data indicate that b1 integrin interaction with IL-3Rbc is crucial for in vivo vasculogenic process in the presence of IL-3. The origin of neovessels from the host vasculogenic or angiogenic cells was excluded as the majority of vessels were lined by human leukocyte antigen class I-positive cells (Supplementary Figure S6) . EPCs are thought to merge with the wall of a growing vessel (Asahara et al., 1997) . Therefore, EPC contribution to tumour vascular growth was evaluated in our model. H-END cells were injected in syngeneic DBA/2 mice. After 2 or 3 weeks, syngeneic-labelled EPCs were injected in the tail vein of these mice. Two weeks after labelled EPC injection, the tumour masses were recovered and analysed. However, we were unable to detect EPCs incorporated into tumour newly formed vessels in both experimental conditions (mice injected with EPCs 2 or 3 weeks after tumour cell injection) (data not shown). Eventually, endothelial cells recovered from primary human tumours (TECs) (Bussolati et al., 2003) , known to form tumour-derived neovasculature (Bussolati et al., 2003; Dentelli et al., 2007) , were injected s.c. into SCID mice in the presence of IL-3, soluble Fc1.3, Fc1.4, Fc4 or the Fc fragments and used as an indirect tumoral angiogenic model. After 5 days, labelled EPCs were injected in the tail vein of these mice, and 2 days later, Matrigel plugs were recovered for immunostaining. As reported in Supplementary Figure  S7 , EPCs represented a minor fraction (less than 5% of the total CD31-positive cells) in mice treated with Fc1.3-or Fc-negative controls, whereas only a few EPCs could be detected in Matrigel plugs in mice treated with Fc1.4 and Fc4, and none of them were incorporated into the vessels (Supplementary Figure S7) . Again, the results confirmed a reduced number of vessels formed by TECs in mice injected with Fc1.4 and Fc4 (Supplementary Figure S7) .
These results are consistent with Fc fusion proteins impairing vasculogenic processes, by functionally interfering with the IL-3Rbc/b1 integrin interplay. Conversely, we have no conclusive data on the impact of cytokine receptor/b1 integrin interaction in controlling EPC recruitment into nascent vessels.
Discussion
Several studies on integrin and receptor tyrosine kinases downstream effectors documented a general role for joint integrin/receptor tyrosine kinase signalling in angiogenesis (Giancotti and Tarone, 2003) . Consistently, IL-3Rbc/b1 integrin complex: a novel antiangiogenetic target B Uberti et al evidence has been provided that b1 integrin, independently of receptor tyrosine kinases, by interacting with the IL-3Rbc 'primes' endothelial cells to progress into the cell cycle in response to IL-3 (Defilippi et al., 2005) .
However, how the two receptors mechanistically interact, and whether their interplay is biologically relevant for vascular growth remains uncertain. Herein, we report the novel finding of the b1 integrin-interacting IL-3Rbc/b1 integrin complex: a novel antiangiogenetic target B Uberti et al domain in the juxta-membrane IL-3Rbc extracellular portion by generating Fc fusion proteins recognizing different domains of the IL-3Rbc extracellular region. In addition, functional studies showed that, by inhibiting IL-3Rbc/b1 integrin interaction, both vasculogenic processes and vessel formation in tumours can be hampered. Tumour expansion is mainly supported by angiogenesis (sprouting cells and co-option of neighbouring preexisting vessels) (Folkman, 2006) . However, emerging evidences indicate that bone marrow -derived EPCs also contribute to this process (Rafii et al., 2002) . Expansion and differentiation of endothelial progenitors are recognized as a dynamic multistage process, in most cases requiring the engagement of adhesion molecules (Bellik et al., 2005) , as well as growth factor and cytokine receptors. Our data indicate that intracellular signals generated by the activation of IL-3Rbc/b1 integrin complex are essential for EPC proliferation and arterial differentiation in response to IL-3. The biological relevance of integrin/cytokine receptor interaction is provided by the following observations: (i) EPCs lacking IL-3Rbc intracellular domain could not be expanded ex vivo any further and were unable to express arterial markers (data not shown); (ii) EPCs cultured in the presence of Fc1.4 or Fc4 retained the ability to adhere, but failed to proliferate or undergo arterial commitment; and (iii) in vivo EPCs failed to form vascular structures in the presence of Fc fusion protein.
EPCs are thought to merge with the wall of a growing vessel, where they differentiate into endothelial cells (Asahara et al., 1997) . However, conflicting evidence has been reported in relation to their contribution to tumour vessel growth (Gao et al., 2008 (Gao et al., , 2009 , ranging from major (Lyden et al., 2001 ) to minor contribution (Peters et al., 2005) or no contribution at all (De Palma et al., 2005) . Consistently, we were unable to show EPC incorporation into tumour nascent vessels when Kaposilike sarcoma cells were used as an in vivo model, although a small number of EPCs was detected in vessels formed by human-derived tumour endothelial cells. Several hypotheses have been postulated to explain these results: (i) tumour types; (ii) tumour-specific microenvironment; and (iii) stages of tumour growth (Nolan et al., 2007; Gao et al., 2009) .
Despite these controversial findings, incorporation of EPCs into tumour vasculature has been reported in cancer patients, and the levels of EPCs were consistently low and dependent on the type of cancer (Peters et al., 2005; Ahn and Brown, 2009 ). Tumour-promoting functions of EPCs have also been inferred from several clinical-pathological studies in which a high number of these cells in the peripheral blood correlated with increased angiogenesis and metastasis associated with reduced patient survival (Gao et al., 2009) . Therefore, interfering with mechanisms regulating mobilization, expansion and recruitment may be essential to overcome their negative consequence in patient survival. Although major efforts are geared towards interrogating mechanisms regulating EPC activation, expansion and mobilization, mechanisms governing their homing and recruitment remain uncertain. Similarly, the role played by integrin receptors in regulating these processes is not definitively clarified. Recently, upregulation of avb5 and a5 integrins has been indicated as a possible mechanism governing homing and recruitment of EPCs in neointima lesions (Schroeter et al., 2008) . Herein, we report that EPCs still retain the ability to adhere to matrix protein, even in the presence of Fc fusion proteins, suggesting that disruption of the IL-3Rbc/b1 integrin complex does not affect their ability to home to neoangiogenetic sites. Although our results are not conclusive, the finding that Fc fusion proteins impaired the ability of EPCs to expand and acquire specification suggests that Fc fusion proteins may represent a valuable tool to prevent both structural and/or paracrine roles of EPCs, ultimately affecting tumour progression.
Soluble factors are directly involved in the angiogenetic process and tumour growth through the recruitment and local expansion of EPCs and stromal cells (Furuya et al., 2009) . Growth factors and cytokines released into the tumour microenvironment also act as signalling molecules promoting vessel sprouting by activating endothelial cell migration, proliferation and survival (Peoples et al., 1995; Dentelli et al., 2004) . Although growth factors and cytokines act directly to induce angiogenesis, integrin receptors provide a permissive environment (Hutchings et al., 2003; Desgrosellier and Cheresh, 2010) . In adherent cells, the interplay between integrins and functional cytokine receptors is required for providing the maximal response to cytokines (Giancotti and Tarone, 2003) . This is particularly true in tumours such as Kaposi-like sarcoma, where the integrity of the IL-3Rbc and the signals induced by the engagement of b1 integrin and IL-3Rbc are essential to promote cell migration and in vivo vascular remodelling. Again, the functional relevance of IL-3Rbc/b1 integrin complex in these processes is supported by the reduced vascular density in those tumours where the signalling axis provided by integrin/cytokine receptor interaction has been disconnected. In addition, the small number of functional vessels formed by TECs exposed to Fc fusion proteins further sustains the potential role of IL-3Rbc/b1 integrin interplay in regulating tumour angiogenesis. Thus, these data indicate that Fc fusion proteins, by impairing instructive (release of pro-angiogenic factors) and structural functions provided by growing vessels, may contribute to inhibit tumour vessel formation and, possibly, tumour progression.
The contribution of T cells in inflammatory and tumour neoangiogenesis has been shown extensively (Naldini and Carraro, 2005; Furuya et al., 2009) . Our data indicate that once T cells become activated, like during an inflammatory response, the release of IL-3 stimulates angiogenesis through IL-3Rbc/b1 integrin interaction. Moreover, in vivo Fc fusion proteins, by functionally interfering with IL-3Rbc and b1 integrin interplay, prevent the neoangiogenetic process. Taken together, these observations lead us to speculate that targeting the IL-3Rbc/b1 integrin molecular complex might confer a significant therapeutic advantage.
In physiological conditions, cell fate is driven by extracellular stimuli, which work in concert to control several biological responses (Streuli and Akhtar, 2009 ). Herein, we show that cytokine receptors and extracellular matrix adhesion receptors operate in a coordinated manner to promote vasculogenic processes and tumour angiogenesis (Figure 6 ). Owing to their critical role in tumour growth, tumoral blood vessels are recognized as potential targets for antitumoral treatments. In conclusion, in view of the failure of clinical trials with antiangiogenic factors, integrin/cytokine receptor interactions may represent an effective molecular target to impair vascular growth in tumours.
Materials and methods

Isolation of EPCs from peripheral blood mononuclear cells
EPCs were isolated from peripheral blood mononuclear cells, recovered from eight normal subjects (five males and three females; age, 40.0±2) and cultured as described previously (Zeoli et al., 2008) , in the presence or in the absence of the indicated Fc fusion proteins. In selected experiments, EPCs were also cultured with or without the indicated Fc fragments in the presence of VEGF (10 ng/ml). The approval was obtained from SIMT (Servizio Immunoematologia e Medicina Trasfusionale, Torino, Italy) and from the Institutional Review Board of the hospital. Informed consent was provided according to the Declaration of Helsinki.
Cell cultures HEK293 human epithelial cells (American Type Culture Collection) and murine H-END endothelioma cells (Giraudo et al., 1996) were cultured in Dulbecco's modied Eagle's medium supplemented with 2 mM glutamine (Life Technologies, Gaithersburg, MD, USA), 10% fetal bovine serum and gentamicin. Endothelial cells were isolated from human umbilical veins within 4 h following delivery and cultured as described previously . Human TECs were grown as described previously (Bussolati et al., 2003) .
Generation and purification of extracellular IL-3Rbc-Fc fusion proteins Fc fusion proteins were generated from IL-3Rbc extracellular domain cDNA to obtain three different fragments: (i) Fc1.4 fusion protein, corresponding to the entire extracellular domain of the IL-3Rbc, amplified using the following primers, 5 0 -ATTGAATTCATGGTCCTGGCC-3 0 (sense) and 5 0 -GAC ACCGAGTCCTCGAGAAT-3 0 (antisense); (ii) Fc1.3 fusion protein, corresponding to domains 1-3, amplified with, 5 0 -AT TGAATTCATGGTGCTGGCC-3 0 (sense) and 5 0 -AAGAGC TCAGTCTCGAGAAT-3 0 (antisense); and (iii) Fc4 fusion protein, corresponding to juxta-membrane domain, amplified with, 5 0 -ACCGAATTCATGAACATCCAG-3 0 (sense) and 5 0 -GACACCGAGTCCTCGAGAAT-3 0 (antisense). The PCR products were used to generate PFUSE constructs containing Fc fragments as described in details in the online Supplementary data.
In vivo vasculogenesis and angiogenesis To evaluate the in vivo vasculogenic process (Zeoli et al., 2008) , SCID mice (Charles River Laboratories Italia Srl, Calco (LC), Italy) (four mice for each experimental group) were injected s.c. with growth factor-reduced Matrigel containing 50 ng/ml IL-3 and 2 Â 10 6 CSFE-labelled EPCs (CSFE, fluorescent dye carboxyfluorescein diacetate succinimidyl ester; Invitrogen Srl, San Giuliano Milanese (MI), Italy), with or without 100 mg/ml IL-3Rbc/b1 integrin complex: a novel antiangiogenetic target B Uberti et al of Fc1.3, Fc1.4 or Fc4. Fifty mg/ml of IgG-Fc fragment was used as a control. After 15 days, Matrigel plugs were removed and processed for immunohistochemistry analysis. FVB mice (Charles River) were used for in vivo inflammatory angiogenesis (Brizzi et al., 1999; Dentelli et al., 1999) . To this end, five mice for each experimental group were injected s.c. with Matrigel containing IL-3 (50 ng/ml) and Fc fusion proteins. After 6 days, FVB mice were killed and Matrigel plugs were processed for histological analysis with hematoxylin-eosin staining. Quantification of neoformed vessels was expressed as percentage ± s.d. of the vessel area to the total Matrigel area ( Â 40 and Â 20 magnification, respectively), planimetrically assessed from 10 randomly stained sections in six different samples, as described previously (Kibbey et al., 1992) . Only vessels possessing a patent lumen containing red blood cells were considered for the study. Detailed experimental proceedings were described in the online Supplementary data.
In vivo tumour growth For in vivo tumour growth, 10 7 H-END cells were injected s.c. into the left flank of the syngeneic DBA/2 mice (Charles River) (five mice for each experimental group) in the presence of IL-3 (50 ng/ml) and Fc fragments (100 mg/ml Fc1.3, Fc1.4 or Fc4 fragments; 50 mg/ml IgG-Fc fragment). The fragments were then injected into the tumours once a week for a total of 4-5 weeks . Tumour size was documented by measuring two perpendicular diameters using a calliper. Tumour volume was calculated using the formula: V ¼ 4/ 3p Â (d/2) 2 Â (D/2) (d stands for minor tumour axis; D stands for major tumour axis). Animals were killed approximately after 4-5 weeks, when tumours reached a volume of B550 mm 3 . Sections from tumours were fixed and processed for histological analysis. Results were expressed as percentage±s.d. of the vessel area to the total tumour area ( Â 20 magnification). Quantification of neoformed vessel density was described in detail in the online Supplementary data. Animal procedures conformed to the Guide for Care and Use of Laboratory Resources.
In vivo EPC contribution to tumour neovasculature EPC contribution to tumour vascular growth was evaluated in DBA/2 mice (four mice for each experimental group) injected with H-END cells or in SCID mice injected s.c. with growth factor-reduced Matrigel containing endothelial cells derived from primary human tumours (TECs) (Bussolati et al., 2003; Dentelli et al., 2007) , as described in detail in the online Supplementary data. The fraction of EPCs incorporated into tumoral vessels was calculated as a percentage of number of Fluorescein/Oregon Green-(Molecular Probes, Invitrogen) positive cells (antibody against CSFE marker) to the total number of CD31-positive stained vascular cells around microvessels (data not shown), counted in 10 randomly selected fields in six different samples.
Reagents and antibodies, silencing of the endogenous b1 integrin by small interfering RNAs, western blot analysis and immunoprecipitation, flow cytometry, plasmid construct, cell transfection, RNA isolation and quantitative real-time PCR, adhesion and migration assays and immunohistochemistry were described in details in the Supplementary data.
Statistical analysis
In vitro and in vivo results are representative of at least three independent experiments, performed in triplicate. Densitometric analysis using a Bio-Rad GS 250 molecular imager was used to calculate the differences in the fold induction of protein activation or expression. Comparison of results between different groups was performed by Newman-Keuls multicomparison test. Differences were considered significant at Po0.05 (* and # ).
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